Joshua Zeidner/ X ; Daniel Peters/ X
Jul 13, 2026, 10:49
Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
Joshua Zeidner, Professor of Medicine at The University of North Carolina at Chapel Hill, shared Daniel Peters‘s post on X, adding:
“True privilege to be part of the MD Education AML ALL US Focus 2026 meeting!
Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN.
Study for newly diagnosed younger/fit KMT2Ar AML.”
Daniel Peters, Assistant Professor at Medical College of Georgia at Augusta University and Member of the Georgia Cancer Center, shared a post on X:
“One of the many great talks at MD Education AML-ALL focus group.
Joshua Zeidner at UNC Lineberger showing continued, impressive results of Menin-I in NPM1 and KMT2Ar AML and emphasis on frontline combos.
Tip of the iceberg!”
-
Oct 20, 2026, 13:20The Global Blood Crisis – Are We Solving the Wrong Problem?
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!